The Oncology Institute, Inc. · NASDAQ:TOI
The Oncology Institute — Oncology Institute — Investor Presentation (March 2025)
21 slides from The Oncology Institute's investor presentation, Mar 24, 2025
Slide 1: Investor Presentation February 2025
1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION QŦǐğƠƬűƘͭ ƘğƠğŦƬôƬńűŦ February 2025
Slide 2: Disclaimer
2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION %ńƠđśôńŤğƘ This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the “ PIP E Financing”) involving The Oncology Institute, Inc. (the “Company”), and for no other purpose. This presentation
Slide 3: The rising cost of oncology care is a significant problem in the U.S.
3 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ¸ĿğͭƘńƠńŦĸͭđűƠƬͭűķͭ|ŦđűśűĸǗͭôƘğͭńƠͭôͭƠńĸŦńǮđôŦƬͭƕƘűĐśğŤͭńŦͭƬĿğͭ¿« of U.S. GDP is spent on healthcare & continues to rise ~18% LğôśƬĿđôƘğͭńƠͭ¿ŦôǫűƘĘôĐśğͭιͭ QŦğǬđńğŦƬͭńŦͭƬĿğͭ¿̱«̱ spent per person compared to OECD average 2x …Yet, U.S. incidence of chronic
Slide 4: TOI is a leading value-based oncology platform
4 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION unique patient encounters in 2024 ~77K Patient visits in 2024 385K clinical trials since TOI was founded, giving patients cutting edge access 200+ ¸|QͭńƠͭôͭśğôĘńŦĸ̲ͭǐôśƴğ ͈ ĐôƠğĘͭƕśôƬķűƘŤͭķűđƴƠğĘͭğǖđśƴƠńǐğśǗͭűŦͭűŦđűśűĸǗ reduction in patient total healthc
Slide 5: TOI is both an oncology benefit manager and oncology care provider
5 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOI is both an oncology benefit manager and oncology care provider. TOI combines the services of a speciality benefits manager withthe care delivery infrastructure of a provider and pharmacy
Slide 6: A combination which is differentiated among marketplace solutions
6 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION a combination which is differentiated among marketplace solutions TOI’s peers at scale are either exclusively a network management model or designed around fee - for - service economics that generate profit positively correlated to drug spend
Slide 7: Fully integrated suite of services across the oncology continuum
7 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION with fully integrated suite of services to deliver care across oncology continuum TOI offers an expansive range of oncology services with a distinctive capability to assume fully-delegated, population-level managed care and capitation contracts, while en
Slide 8: Differentiated clinical model delivers superior results to patients and payors
8 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOIs differentiated clinical model delivers superior results to patients and payors TOIs clinicians and population health tools create integrated, value-based model focused on quality care at lower cost Notes: 1 Based on study on TOI patient population c
Slide 9: Scalable model with multi-market presence and large whitespace opportunity
9 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOI benefits from a scalable model, with existing multi-market presence, and large remaining whitespace opportunity Notes: 1 Represents Medicare Advantage, ACO/DCE, Managed Medicaid, Exchange and Commercial HMO lives. Lives based on published statistics
Slide 10: Financial Overview
10 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION financial overview
Slide 11: TOI Revenue and Milestone Timeline
10 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION TOI Revenue1 and Milestone Timeline TOI represents 0.2% of the U.S. Oncology Market, providing substantial growth opportunity (1) 2007-2017 revenue is cash basis, unaudited and pertains to the Predecessor entity only (2) Predecessor revenue of $76M; Suc
Slide 12: TOI is on the path to break even in 2025
12 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ¸|QͭńƠͭűŦͭƬĿğͭƕôƬĿͭƬűͭĐƘğôŘͭğǐğŦͭńŦͭˢˠˢ˥ Three key sources of contribution as TOI enters 2025… • TOI continues to sign new contracts at an accelerated pace • These contracts require lower marginal cost, given they are utilizing TOI’s existing clinical c
Slide 13: Supported by multiple drivers of revenue growth and margin expansion
13 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ̵ƠƴƕƕűƘƬğĘͭĐǗͭŤƴśƬńƕśğͭĘƘńǐğƘƠͭűķͭƘğǐğŦƴğͭĸƘűǑƬĿͭôŦĘͭŤôƘĸńŦͭğǖƕôŦƠńűŦͭǑńƬĿńŦͭ ¸|Q͕ƠͭĘńǐğƘƠńǮğĘͭĐƴƠńŦğƠƠͭŤűĘğś Patient Services (Medical & Radiation Oncology) Drug Dispensing Clinical Trials Other 1 Revenue Mix Future Volume Growth Margin Contribution Lo
Slide 14: Including strong momentum in new capitation contract starts
14 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ̵ńŦđśƴĘńŦĸͭŤűŤğŦƬƴŤͭńŦͭŦğǑͭđôƕńƬôƬńűŦͭđűŦƬƘôđƬͭƠƬôƘƬƠ 2Q24 3Q24 4Q24 1Q25 20K 60K 20K 250K -- 240K Contract Starts – Value - Based Lives 1 3 2 4 -- 5 Contract Starts – Contract Count $12 $24 $26 $6 NA $3 Contract Starts – Average PMPM -- - 13K -- -- - 8
Slide 15: TOI is profitable at a market level, with infrastructure for growth
TOI is profitable at a market level, with infrastructure in place to support additional growth at high contribution rate in 2025
Slide 16: TOI has P&L momentum exiting 2024
TOI has P&L momentum exiting 2024 2024 Revenue Model 124 2H24 Mo Revenue Gross Profit Contribution $26M $28M $54M Market G&A -$22M -$23M i | -$45M Market Contribution $4M $5M $9M Corporate G&A -$24M -$2IM -$45M Adjusted EBITDA -$20M -$16M -$36M @ ne oncotoar enmute OF HOPE & AWOVATION 16
Slide 17: TOI is profitable at a market level, with infrastructure for growth
TOI is profitable at a market level, with infrastructure in place to support additional growth at high contribution rate in 2025 The landscape of solutions in the market to address this issue while supporting quality are limited TOI is one of the first, single-stop models capable of reducing costs w
Slide 18: Historical Financials
Historical Financials @ ne ovcotoar nermute OF HOPE ANOVATION
Slide 19: Historical Financials
Historical Financials rovaezsenmnn0% ronveannece eed mins tpsosom | bweasom nan a024 Sop. 204 | orenaen4 owe aL 2022 eest zon one mamne = seas) sane) sanm| sera] gaara] ssoar| sears | smusoe | sanaass otery meme | mao | akaso| 80s aaes | anes | ma tata te wos) woe| zo) tate |—nams| cass | aco) a ae
Slide 20: Historical Financials
Historical Financials FORTIREE MONTHS ENDED FoRYEAR ENDED pevonesas un 30,2023. $0p 30,2023 bec 12023 um30,2024 $9820 pee at. 2024 dec 84.2022 ove 24,2028 Dec 34.2004 Loss trom operations (04996) (3925) 5200) (8988) (R45) ——(ne29)——(aLAB TOW) (60s) ‘otmer non-operating expense (income) Insert erpose
Slide 21: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Fon THREE MONTHS ENDED Fon ean Noe Inthousande 4un20,202880p20,2023 bec 3.2023 4n300%4 &4p30,2024 Dee 40M Ove} 2022 Dwe 2022 owe 3.2024 Net (oz) income $006907) | scare) | $8754) | _$.05478) scan) $0312) $152 $(s3068) | (64663) Depreciation and neriaton 1220 eee wr) ew
Oncology Institute — Investor Presentation (March 2025) on 6ix